Leprecan
| leucine proline-enriched proteoglycan (leprecan) 1 | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Symbol | LEPRE1 | ||||||
| NCBI gene | 64175 | ||||||
| HGNC | 19316 | ||||||
| OMIM | 610339 | ||||||
| RefSeq | NM_022356 | ||||||
| UniProt | Q32P28 | ||||||
| Other data | |||||||
| Locus | Chr. 1 p34.1 | ||||||
| |||||||
Leprecan is a protein associated with osteogenesis imperfecta[1] type VIII.
Leprecan is part of a superfamily of 2OG-Fe(II) dioxygenase, along with DNA repair protein AlkB, and disease resistant EGL-9. The enzyme was found to be a type of hydroxylases used in the substrate formation of protein glycosylation.[2]
Activities
Leprecan, a proteoglycan, has demonstrated prolyl hydroxylase activity; prolyl hydroxylases hydroxylate proline residues.[3] Prolyl 3-hydroxylase 1, P3H1, forms a larger complex with CRTAP and cyclophilin B, CyPB, in the endoplasimic reticulum. The complex hydroxylates a single proline residue, Pro986, on collagen chains.[4] Recessive forms of Osteogenesis Imperfecta are partly caused by a mutation in the LEPRE1 gene that encodes prolyl 3-hydroxylase 1; malfunctioning prolyl 3-hydroxylase in leprecan leads to inappropriate collagen folding due to instability caused by the absence of hydroxyproline, the product of hydroxylating a proline residue.[5]
References
- ^ Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, Makareeva E, Kuznetsova NV, Rosenbaum KN, Tifft CJ, Bulas DI, Kozma C, Smith PA, Eyre DR, Marini JC (March 2007). "Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta". Nature Genetics. 39 (3): 359–65. doi:10.1038/ng1968. PMC 7510175. PMID 17277775.
- ^ Aravind L, Koonin EV (2001-02-19). "The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases". Genome Biology. 2 (3): RESEARCH0007. doi:10.1186/gb-2001-2-3-research0007. PMC 30706. PMID 11276424.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Lauer M, Scruggs B, Chen S, Wassenhove-McCarthy D, McCarthy KJ (July 2007). "Leprecan distribution in the developing and adult kidney". Kidney International. 72 (1): 82–91. doi:10.1038/sj.ki.5002269. PMID 17495866.
- ^ Chang W, Barnes AM, Cabral WA, Bodurtha JN, Marini JC (January 2010). "Prolyl 3-hydroxylase 1 and CRTAP are mutually stabilizing in the endoplasmic reticulum collagen prolyl 3-hydroxylation complex". Human Molecular Genetics. 19 (2): 223–34. doi:10.1093/hmg/ddp481. PMC 2796888. PMID 19846465.
- ^ Homan EP, Lietman C, Grafe I, Lennington J, Morello R, Napierala D, Jiang MM, Munivez EM, Dawson B, Bertin TK, Chen Y, Lua R, Lichtarge O, Hicks J, Weis MA, Eyre D, Lee BH (January 2014). "Differential effects of collagen prolyl 3-hydroxylation on skeletal tissues". PLoS Genetics. 10 (1): e1004121. doi:10.1371/journal.pgen.1004121. PMC 3900401. PMID 24465224.
{{cite journal}}: CS1 maint: unflagged free DOI (link)
External links
- leprecan+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
.svg){kind=small} | This biochemistry article is a stub. You can help Wikipedia by expanding it. |